Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?

Key event: head-to-head data show Eli Lilly's Zepbound produced mean weight loss of 20.2% vs. Novo Nordisk's Wegovy at 13.7% at 72 weeks, and Lilly's triple agonist retatrutide achieved 28.7% mean weight loss at 68 weeks. Product and pipeline positioning favors Eli Lilly (oral GLP-1 orforglipron launching in Q2 and diversified franchises like Verzenio and Taltz), while Novo has oral Wegovy and next-gen candidates (CagriSema, UBT251). Valuation contrast is large: Lilly at 26.6x forward EPS vs. Novo at 10.9x (healthcare avg 16.9x), implying higher expectations for Lilly despite being deemed the better long-term buy.

Analysis

Market leadership in GLP-1s is starting to be decided less by headline trial wins and more by modality mix, payer economics, and manufacturing footprint. Oral formulations convert a one-time specialty-clinic decision into chronic primary-care prescribing and retail pharmacy reimbursement — that structural shift lowers gross per-injectable ASPs but expands volume and drives recurring revenue that favors players with dual oral+injectable capacity and integrated commercial teams.

Second-order winners include CDMOs and cold-chain logistics providers: ongoing demand for high-volume peptide production and novel formulation work (enteric coatings, lipid carriers) creates multi-year backlog and pricing power for contract manufacturers, while a tilt to oral agents reduces marginal demand for refrigerated warehousing per dose shipped. Conversely, specialty pharmacy exclusivity deals and high ASPs are the first things payers target; expect formulary pressure and outcomes-based contracting to accelerate within 12–24 months and compress realized pricing unless manufacturers secure durable medical benefit coding.

Key risks that could reverse current positioning are safety/regulatory surprises in cardiovascular or long-term metabolic endpoints, aggressive payer mandates (step edits, utilitarian duration limits) that reduce average treatment duration to <12 months, and faster-than-expected biosimilar/novel-chem copycats driving price erosion. Time horizons matter: commercial/coverage shifts play out in quarters-to-years, manufacturing and pipeline readthroughs over 12–36 months, and regulatory/label shocks can occur in days to weeks around advisory panels or new safety signals.

Key Decisions for Investors

• Pair trade: Long LLY (outright or 6–12 month call spread) / Short NVO (equal $ exposure) — timeframe 6–18 months. Rationale: capture asymmetric upside from diversified oncology/autoimmune franchises plus upcoming oral/tri-agonist read-throughs while neutralizing macro/healthcare beta. Target reward ~15–30% vs tail risk ~25% if regulatory/payer outcomes swing the other way; size to 1–2% portfolio risk.
• Event option trade: Buy LLY 12-month call (or call spread) concentrated around next major retatrutide commercialization readouts — cost-limited upside with defined loss = premium. If positive execution, expect 2–4x payoff; if negative, loss limited to premium (size 0.5–1% portfolio).
• Hedge / asymmetric short on NVO: Purchase 12-month puts (25–35% OTM) sized to 0.5–1% portfolio or sell near-term calls to fund puts. This expresses conviction that payer pressure and slower margin recovery will lag headline rebounds; potential payoff 3x+ if pricing compresses, with known downside (premium paid).
• Supply-chain long: Initiate a selective long (6–18 months) in high-quality CDMOs with peptide/biologic capacity (e.g., CTLT or TMO) to capture multi-year backlog and pricing power tied to GLP-1 manufacturing demand. Expect steady revenue uplift and margin expansion; risk is capex-led dilution if overbuilt capacity emerges.